ILMN Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 16.94% compared to Illumina's net margin of -22.5%. Illumina's return on equity of -35.09% beat Delcath Systems's return on equity of -117.89%.

Illumina has a consensus price target of $115.55, signalling upside risk potential of 48.37%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 81.45%. Given that Delcath Systems has higher upside potential than Illumina, analysts believe Delcath Systems is more attractive than Illumina.

Illumina has a beta of 1.349, which suggesting that the stock is 34.945% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.805%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Illumina quarterly revenues are $1.1B, which are larger than Delcath Systems quarterly revenues of $15.1M. Illumina's net income of $187M is higher than Delcath Systems's net income of -$3.4M. Notably, Illumina's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.84x versus 9.80x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics has a net margin of 16.94% compared to Illumina's net margin of 8.3%. Illumina's return on equity of -35.09% beat Quest Diagnostics's return on equity of 13.14%.

Illumina has a consensus price target of $115.55, signalling upside risk potential of 48.37%. On the other hand Quest Diagnostics has an analysts' consensus of $183.33 which suggests that it could grow by 3.03%. Given that Illumina has higher upside potential than Quest Diagnostics, analysts believe Illumina is more attractive than Quest Diagnostics.

Illumina has a beta of 1.349, which suggesting that the stock is 34.945% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.524, suggesting its less volatile than the S&P 500 by 47.572%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.71% to investors and pays a quarterly dividend of $0.80 per share. Illumina pays -- of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Quest Diagnostics quarterly revenues of $2.7B. Illumina's net income of $187M is lower than Quest Diagnostics's net income of $220M. Notably, Illumina's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 22.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.84x versus 1.99x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 16.94% compared to Illumina's net margin of -14.32%. Illumina's return on equity of -35.09% beat Exact Sciences's return on equity of -35.57%.

Illumina has a consensus price target of $115.55, signalling upside risk potential of 48.37%. On the other hand Exact Sciences has an analysts' consensus of $68.81 which suggests that it could grow by 33.49%. Given that Illumina has higher upside potential than Exact Sciences, analysts believe Illumina is more attractive than Exact Sciences.

Illumina has a beta of 1.349, which suggesting that the stock is 34.945% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Illumina quarterly revenues are $1.1B, which are larger than Exact Sciences quarterly revenues of $706.8M. Illumina's net income of $187M is higher than Exact Sciences's net income of -$101.2M. Notably, Illumina's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.84x versus 3.38x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 16.94% compared to Illumina's net margin of 6.36%. Illumina's return on equity of -35.09% beat Labcorp Holdings's return on equity of 9.01%.

Illumina has a consensus price target of $115.55, signalling upside risk potential of 48.37%. On the other hand Labcorp Holdings has an analysts' consensus of $271.29 which suggests that it could grow by 9.54%. Given that Illumina has higher upside potential than Labcorp Holdings, analysts believe Illumina is more attractive than Labcorp Holdings.

Illumina has a beta of 1.349, which suggesting that the stock is 34.945% more volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.43%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.16% to investors and pays a quarterly dividend of $0.72 per share. Illumina pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Illumina's net income of $187M is lower than Labcorp Holdings's net income of $212.8M. Notably, Illumina's price-to-earnings ratio is -- while Labcorp Holdings's PE ratio is 28.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.84x versus 1.58x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.